Increasing bacterial resistance to
antibiotics is a worldwide ongoing issue. Urgent need for new
antibacterial agents has resulted in significant research efforts, with new molecules proposed for use in clinical practice. However, as highlighted by many groups this process does not have an optimal rhythm and efficacy, to fully combat highly adaptive germs, particularly in the intensive care units. This review focuses on the last three years of novel FDA approved
antibacterial agents (2015-2017):
ceftazidime/avibactam,
obiltoxaximab, bezlotoxu-mab,
delafloxacin,
meropenem/vaborbactam,
ozenoxacin.
Ceftazidime/avibactam and
meropenem/ vaborbactam are new players in the field of resistant bacteria treatment.
Ceftazidime/avibactam is validated in selected patients with complicated urinary or
intra-abdominal infections, hospital and
ventilator-associated pneumonia.
Meropenem/ vaborbactam gained approval for the cases of complicated
urinary tract infections. Other potential indications are under investigation, widened and validated by future studies.
Obiltoxaximab is a
monoclonal antibody that can be used in the prevention and treatment of inhalational
anthrax.
Bezlotoxumab monoclonal antibody is an useful and specific tool for the management of recurrent
Clostridium difficile infection.
Delafloxacin is approved for patients with acute skin or skin structure
infections. Despite recent progress, it is imperative to continue the development of new
antibiotic drugs and new strategies to counteract resistance to
antibiotics.